Entera Bio Ltd.
ENTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -48.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | 0% | 0% |
| R&D Expenses | $2 | $2 | $1 | $1 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $2 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $2 |
| Operating Income | -$3 | -$3 | -$3 | -$2 |
| % Margin | – | – | -6,102.4% | -2,850% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$3 | -$3 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | -$3 | -$2 |
| % Margin | – | – | -6,111.9% | -2,875.6% |
| EPS | 0.07 | -0.057 | 0.06 | -0.063 |
| % Growth | 223.5% | -194.5% | 195.2% | – |
| EPS Diluted | 0.07 | -0.057 | 0.06 | -0.063 |
| Weighted Avg Shares Out | 47 | 47 | 43 | 38 |
| Weighted Avg Shares Out Dil | 47 | 47 | 43 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$3 | -$2 |
| % Margin | – | – | -6,083.3% | -2,836.6% |